Alkermes’s disappointment hones melanoma niche focus
June 04, 2021 | Source: Madeleine Armstrong, Evaluate Vantage Alkermes plays up responses in mucosal melanoma, but those hoping for…
Melanoma Research
06/04/2021
Alkermes’s disappointment hones melanoma niche focus
June 04, 2021 | Source: Madeleine Armstrong, Evaluate Vantage Alkermes plays up responses in mucosal melanoma, but those hoping for…
|
|
05/21/2021
Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma
PRINCETON, N.J.–(BUSINESS WIRE)– Bristol Myers Squibb (NYSE: BMY) today announced new six-and-a-half-year data from CheckMate -067, a randomized, double-blind, Phase 3…
|
|
04/15/2021
Initial Treatment With Tebentafusp Show Significant OS Improvement in Metastatic Uveal Melanoma
Published: April 10, 2021, Kristi Rosa in Targeted Oncology In patients with metastatic uveal melanoma, frontline treatment with tebentafusp…
|
|
04/14/2021
Lifileucel Proves Efficacy in Pretreated Advanced Melanoma
Published: April 12, 2021, Lisa Astor in Oncology Nursing News Lifileucel produced durable responses in advanced melanoma that was previously…
|
|
03/11/2021
FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma
March 11, 2021 | Source: PRNewswire DUBLIN, March 11, 2021 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced…
|
|
02/05/2021
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
March 11, 2021| Source: PRNewswire Alkermes plc (Nasdaq: ALKS) today announced that nemvaleukin alfa (“nemvaleukin”, formerly referred to as…
|
|
01/26/2021
FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma
January 24, 2021 19:07 ET | Source: Junshi Biosciences Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical…
|
|
01/08/2021
Why Is the Tissue Bank So Important For Melanoma Research?
We answer this question with the help of Mohammed Kashani-Sabet, M.D., the Director, Center for Melanoma Research and Treatment;…
|
01/08/2021
What is Oral Parity, and Why Does it Matter?
We answer this question with the help of a pharmacist at a large oncology practice who wishes to remain…
|
11/24/2020
Immunocore’s Tebentafusp Successfully Activates T Cells Against Uveal Melanoma
Published: Nov 23, 2020 By Mark Terry in BIOSPACE Immunocore, based in Oxfordshire, England, Conshohocken, Pennsylvania and Rockville, Maryland, announced that its Phase…
|
|
Recent Posts
May. 14, 2025
Parenting Through Cancer
May. 09, 2025
Tri-State Melanoma Consortium – Inaugural Convening
May. 01, 2025
AIM at Melanoma + WEARSPF®: Partnering for a Cause This Melanoma Awareness Month
May. 01, 2025
Hope, Purpose, and Progress: Melanoma Awareness Month with AIM
Apr. 28, 2025